to patients with RA, is a question that needs to be addressed 7 . Is this a result of the separation of health services into physical and mental health? Or does it reflect an ingrained Cartesian dualism that views the mind as separate from the body and brain and consequently supports a view of depression as an 'understandable' reaction to physical disease? Evidence from human experimental medicine studies is beginning to emerge that suggests this idea could be refuted. Many studies have now convincingly demonstrated that even modest increases in pro-inflammatory cytokines function in the brain to induce many of the motivational, cognitive and emotional features of depression including insomnia and fatigue 8 . So rather than being an 'emotional reaction' to disease, it is becoming increasingly apparent that mental health symptoms are likely to be an intrinsic component of the pathology of RA and other inflammatory disorders.
A final result reported by Matcham et al. 3 relates to their use of a network meta-analysis to indirectly compare csDMARDs and bDMARDs with different modes of action on mental health outcomes, even in the absence of direct head-to-head trials. Using this approach, they demonstrated that regardless of the mode of action, bDMARDs (including TNF inhibitors, B cell inhibitors, T cell inhibitors, IL-6 blockers and Janus kinase inhibitors) performed better than csDMARDs for improving mental (and physical) health 3 . Although the authors detected no notable differences in mental health outcomes between different bDMARDs, they performed a surface under the cumulative ranking curve (SUCRA) ana lysis to estimate the probabilities that each mode of treatment was the best, the second best and so on. This approach revealed that although abatacept had an 83% probability of being the most effective treatment for improving physical health, biologic agents targeting anti-IL-6 had a 90% probability of being the most effective DMARD for mental health outcomes 3 . This finding is noteworthy, as increased levels of IL-6 have been repeatedly reported in idiopathic depression, whereas findings for TNF are more variable 9 . Whether these apparent mental health benefits of anti-IL-6 therapies hold up in clinical trials will become evident when the results of two on-going phase II trials of tocilizumab and sirukumab in major depression are reported 10 . Whether perceived as a comorbidity or as an integral part of the inflammatory process that underlies RA, mental health symptoms remain poorly recognized and managed in these patients. This problem might relate to a lack of diagnostic tools, relevant clinical expertise or suitable care pathways. Further investment in both basic and clinical research in this domain, 
N e w s & V i e w s
In 1989, Charles Janeway predicted the existence of pattern-recognition receptors (molecules that serve to detect microbial molecular motifs that are distinct from self) as a fundamental principal of immunity. Since that time, our understanding of innate immune signalling has expanded, with the discovery of important molecules that can sense pathogenderived nucleic acid; these molecules function as primary triggers of an antiviral type I interferon-mediated response, and knowledge of this pathway is rapidly progressing.
In particular, the identification of stimulator of interferon genes (STING) by Ishikawa and Barber in 2008, and cyclic GMP-AMP synthase (cGAS) in 2013 by the team of James Chen represent seminal discoveries. cGAS is the major sensor of cytosolic DNA (a danger signal that indicates viral and bacterial infection) that catalyses the production of a second messenger cyclic GMP-AMP (cGAMP); this messenger activates STING, which subsequently induces type I interferon production 1 ( Fig. 1) . Now, in a new paper published in Nature, Haag et al. describe the discovery and characterization of potent and selective small-molecule antagonists of STING 2 ; as well as helping to advance our knowledge of this pathway, the findings provide a new therapeutic avenue for type I interferon-driven diseases. Although the STING-mediated response to cytosolic DNA is a highly effective antiviral strategy, viral DNA and RNA sensors can also detect self-derived nucleic acids. The existence of type I interferonopathies, a spectrum of monogenic diseases characterized by inborn errors of immunity that enhance type I interferon production, highlights the risk of employing nucleic acid sensing as an antiviral strategy 3 . Furthermore, cytosolic
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Stimulator of interferon genes (STING), an important component of the cytosolic DNA sensing pathway , is an attractive therapeutic target for ameliorating interferon-driven systemic inflammation. New findings are shedding light on how STING functions and on a strategy to target STING therapeutically. volume 14 | SePTemBeR 2018 | 509 NaTuRe ReviewS | RheumAToloGy N e w s & V i e w s signalling of DNA through the cGAS-STING axis has been implicated in a broad range of human diseases 4 . Consequently, the importance of strategies that can either block or activate elements in this pathway has become apparent, piquing the interest of pharmaceutical companies that are developing relevant therapeutic compounds. Using a cell-based chemical screen, Haag et al. 2 identified molecules that could inhibit STING-mediated signalling by targeting the poorly characterized N-terminus of the protein, which includes its transmembrane domains. They then systematically interrogated the effect of individually mutating amino acid residues in this region of STING on its sensitivity to the identified compounds, and identified a STING mutant with a cysteine-to-alanine substitution at position 91 that was entirely resistant to inhibition by the compounds. This inhibition did not affect the trafficking of STING to the Golgi apparatus, or the subsequent endolysosomal degradation of STING. Instead, this specific cysteine residue is post-translationally modified by the attachment of the fatty acid palmitic acid (palmitoylation), and interaction with the inhibitor renders the cysteine residue unable to undergo palmitoylation. This modification is important, since the authors show that palmitoylation is associated with the assembly of STING into clusters, forming a multimeric complex that enables STING to interact with the downstream serine/threonine-protein kinase TBK1 and then trigger type I interferon production.
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Haag and colleagues 2 went on to test one of their inhibitors in an in vivo system. Trex1-null mice develop an interferon-dependent inflammatory phenotype caused by the persistent activation of the cGAS-STING pathway, representing a model of the first described Mendelian type I interferonopathy, AicardiGoutières syndrome (AGS). Treatment of these mice with the STING inhibitor resulted in a marked amelioration of interferon-driven systemic inflammation. Using the insights gained from this work, and given the conservation of palmitate-modified cysteines between mouse and human STING, the authors then identified two structurally related compounds that are capable of inhibiting the human protein via the same mechanism. Taken together, these data both define highly selective smallmolecule antagonists of STING, and shed new light on the activation of STING.
These results 2 are of potential interest for the treatment of a number of monogenic type I interferonopathies including AGS, STINGassociated vasculopathy of infancy (SAVI) and deficiency of DNase II activity. Furthermore, these findings might have important implications in the broader fields of inflammatory disease and cancer 5, 6 . However, although the therapeutic possibilities are exciting, there are reasons to be cautious. One obvious concern with blocking STING activity is the risk of infection. However, the loss of only one allele of the genes encoding either cGas, Sting or Irf3 ameliorates the otherwise lethal inflammatory phenotype of Trex1-null mice 7 , perhaps indicating that future therapies blocking type I interferon signalling might demonstrate clinical efficacy at doses that do not entail iatrogenic immunodeficiency. A possibly instructive example in this regard is the use of Janus kinase inhibitors for certain type I interferonopathies. These molecules have been trialled on the premise of blocking signalling immediately downstream of the type I interferon receptor and, despite initial concerns, have so far not been associated with a major increase in infection frequency.
A second issue with STING-targeted therapy for autoinflammatory diseases relates to evidence that STING functions as a negative regulator of inflammation in certain contexts. For example, STING can act as a suppressor of inflammation in a mouse model of systemic lupus erythematosus. STING-deficient autoimmune-prone mice have markedly increased lymphoid hypertrophy, autoantibody production, serum cytokine levels and other indicators of immune activation compared with STING-sufficient littermates 8 . Similarly, the antiviral drug ganciclovir induces a type I interferon response in microglia through activation of the STING pathway, inhibiting inflammation and disease development in a mouse model of multiple sclerosis 9 . Finally, of possible note, haploinsufficiency of the STING-activated kinase TBK1 has been described as a cause of amyotrophic lateral sclerosis and frontotemporal dementia 10 . A negative regulatory role for STING could have important implications for STING-directed therapies, highlighting the need for caution owing to the potential to perturb a homeostatic milieu that tries to balance protective immunity and the risk of autoinflammation. Despite this concern, the identification of discrete STING antagonists has clear interest as a future tool in the anti-inflammatory armamentarium. 
